Revenio Group Corporation: Revocation of the share split in item 16 of the convocation of Revenio's Annual General Meeting will be removed from the agenda

Revenio Group Corporation, Stock Exchange Release, March 13, 2020 at 14:30

Revenio Group Corporation: Revocation of the share split in item 16 of the convocation of Revenio's Annual General Meeting will be removed from the agenda

 

The Board of Directors of Revenio Group Corporation has decided to withdraw the issue of share issue without payment (split of shares) in section 16 of the notice of the Annual General Meeting and the matter will not be discussed at the Annual General Meeting. In the opinion of the Board of Directors, the stock market situation has changed significantly, and the planned action is not timely.

 

Revenio Group Corporation's Annual General Meeting will be held on Thursday, March 19, 2020, at 4:00 pm at Finlandia Hall, Veranda 2 Hall, Mannerheimintie 13e, 00100 Helsinki (entrance M4 / K4). Reception of the registration for the meeting and distribution of the voting tickets will begin at 3:00 pm.

 

Revenio Group Corporation

Board of Directors

 

Further information:

CEO and President Timo Hildén

tel. +358 40 580 4774

timo.hilden@revenio.fi          

www.revenio.fi

 

DISTRIBUTION:

Nasdaq Helsinki Ltd

Financial Supervisory Authority

Main media

www.revenio.fi

 

Revenio Group in brief

 

Revenio, a health technology group operating in the international markets, is one of the global leaders in ophthalmic appliances.

 

The Revenio Group consists of Icare Finland Oy, Icare USA Inc., Revenio Italy S.R.L, CenterVue SpA, CenterVue Inc, Revenio Research Oy and Oscare Medical Oy.

 

The common denominators of Revenio's business operations include patient-oriented screening, follow-up and the global need to make cost savings through preventive health care. Revenio seeks vigorous growth in health technology. Revenio aims to develop even more efficient and easily adopted methods for the early-stage detection of diseases with significance for public health. The aim is to improve the quality of life through health technology solutions which enable more effective diagnostics. Revenio Group’s focus is on the early detection of glaucoma, diabetic retinopathy and macular degeneration, and the monitoring of these during the treatment process. Revenio Research concentrates on the commercialization of systems supporting the diagnosis of and treatment planning for skin cancer and asthma.

 

In 2019, Revenio Group's net sales totalled EUR 49.5 million, with its net operating profit standing at 25.5%. Revenio Group Corporation is listed on Nasdaq Helsinki.

 

 

Subscribe